PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy. Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and has a very poor prognosis. Due to the high invasiveness and aggressiveness of GBM, there is considerable interest in programmed...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2021-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|